Markets

NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date

Oct 19, 2026 · 08:38 AM ET· updated 1h ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central

Why It Matters

NRx finished testing batches of a new ketamine medicine under real conditions. This shows they are moving toward selling it, which regulators track carefully.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NRXP2.63

+0.03 (+1.15%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.